Results for koinfekuotiems translation from Lithuanian to English

kraujo sutrikimai hcv/Živ koinfekuotiems pacientams
haematological abnormalities in hcv/hiv co-infected patients:

kraujo sutrikimai hcv/ziv koinfekuotiems pacientams:
haematological abnormalities in hcv/hiv co-infected patients:

duomenų apie epclusa vartojimą pacientams, koinfekuotiems hcv ir hbv, nėra.
there are no data on the use of epclusa in patients with hcv/hbv co-infection.

duomenų apie harvoni vartojimą pacientams, koinfekuotiems hcv/hbv, nepakanka.
there are limited data on the use of harvoni in patients with hcv/hbv co-infection.

kepenų dekompensacija hcv/Živ koinfekuotiems pacientams, sergantiems progresavusia ciroze.
hepatic decompensation in hcv/hiv co-infected patients with advanced cirrhosis

kepen dekompensacija hcv/ziv koinfekuotiems pacientams, sergantiems progresavusia ciroze:
hepatic decompensation in hcv/hiv co-infected patients with advanced cirrhosis:

· negalima pradti skirti pegasys ziv-hcv koinfekuotiems pacientams, kurie serga kepen
· initiation of pegasys is contraindicated in hiv-hcv patients with cirrhosis and a child-pugh

ligoniams, koinfekuotiems hcv/ziv, gydymo rebetol ir peginterferono alfa-2b deriniu trukm yra 48 savaits.
for hcv/hiv co-infected patients, the duration of treatment of rebetol in combination with peginterferon alfa-2b is 48 weeks.

vaisto saugumo koinfekuotiems pacientams, kurių cd4+ ląstelių skaičius < 200/mkl, duomenų turima mažai.
limited safety data are available in co-infected patients with cd4+ cell counts <200/µl.

vaisto saugumo koinfekuotiems pacientams, kuri cd4+ lsteli skaicius 200/µl, duomen turima mazai (n=51) .
limited safety data (n= 51) are available in co-infected patients with cd4+ cell counts 200/µl.

pacientai koinfekuoti ziv ir gydomi labai aktyvia antiretrovirusine terapija (laart) turi padidint laktoacidozs atsiradimo rizik.
patients co-infected with hiv and receiving highly active anti-retroviral therapy (haart) may be at increased risk of developing lactic acidosis.